Loading…
Loading…
GELS does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GELS and 80,000+ other tickers.
See exactly how GELS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GELS and 80,000+ other tickers.
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
MELBOURNE, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) ("Gelteq" or the "Company"), a biotechnology company developing a proprietary gel-based delivery platform for pharmaceutical, animal health and consumer health applications, today provided a corporate update on recent clinical and commercial milestones toward broader pharmaceutical adoption. Highlights Over the first half of 2026, Gelteq has commenced veterinary and pharmaceutical development programs, expanded its delivery platform, and advanced toward future clinical milestones including: Human clinical trial planning completed and the clinical trial is expected to commence next quarter (beginning July 1, 2026), which is anticipated to advance Gelteq's pharmaceutical program toward a potential FDA regulatory pathway; Veterinary clinical trial commenced for an antiparasitic drug candidate, supporting a planned FDA application targeted for later in 2026 in a global animal health market estimated to exceed US$78 billion1; Preclinical diabetes study commenced, expanding the pharmaceutical pipeline into a major chronic-disease category; Development underway in our research facilities to incorporate peptides and peptide-based therapeutics into stable oral formulations, spanning compounds traditionally delivered by injection and an emerging generation of therapies in development; Signed a strategic debt financing of up to US$3.5 million with an institutional investor to advance our clinical programs and accelerate commercialization; Veterinary palatability trials with Kemin Industries completed, demonstrating strong canine acceptance and confirming Gelteq's ability to mask bitter functional ingredients; Commercial product manufactured for a new customer in the East Asian region, demonstrating Gelteq's ability to formulate, manufacture and deliver at commercial scale; Center of Excellence established in Guangdong Province, China, providing strategic access to one of the world's fastest-growing pharmaceutical ecosystems; and Continued expansion of the active pharmaceutical ingredient (“API”) pipeline across multiple therapeutic categories.
MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited ("Gelteq" or the "Company") today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries ("Kemin"), a leading U. S. -based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq technology, the Company's proprietary gel-based delivery platform.
MELBOURNE, Australia, June 12, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”) today announced the successful completion of its veterinary palatability trials conducted in collaboration with Kemin Industries (“Kemin”), a leading U.S.-based global ingredient manufacturer. The trials were designed to optimise flavour profiles and assess canine acceptance of products powered by Gelteq® technology, the Company's proprietary gel-based delivery platform.
MELBOURNE, Australia, June 04, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the establishment of a new Gelteq Center of Excellence in Guangdong Province, China. The Gelteq Center of Excellence will serve as a strategic regional hub enabling deeper integration with and strategic access to one of the world's fastest-growing pharmaceutical and biotechnology ecosystems.
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector. The clinical trial seeks to support Gelteq's planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.